Glooko touted data today from a feasibility study evaluating the impact of its mobile insulin dosing system for people with Type II diabetes who are taking long-acting insulin.
The Mountain View, Calif.-based company said it hoped to better understand the extent to which its system can make appropriate insulin titration adjustments and improve a patient’s glycemic status.
Get the full story at our sister site, Drug Delivery Business News.
The post Study: Glooko’s mobile app boosts glycemic control in patients with Type II diabetes appeared first on MassDevice.
from MassDevice http://ift.tt/2iOEv8t
Cap comentari:
Publica un comentari a l'entrada